{"product_id":"il15-il15ra-lentivirus-bhv18200013","title":"IL15\/IL15Ra Lentivirus","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-license-box{background:#f5f5f5;border:1px solid #ddd;border-radius:4px;padding:12px 16px;font-size:14px;color:#444}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n\u003ch2\u003eScientific Background\u003c\/h2\u003e\n\u003cp\u003eIL15 (interleukin 15) and its high affinity receptor (IL15R) are involved in NK cell development and proliferation and persistence of CD8\u003csup\u003e+\u003c\/sup\u003e T cells, NKT cells, δγT cells and NK cells. The use of membrane bound IL15 as part of the CAR in T cells has been in use for a few years, as a way to improve T cell persistence in vivo. IL15 has a short half-life and requires treatment in high dosages, so research into ways to increase its potency has been ongoing. RLI-15 (receptor-linker-IL-15) is considered a super agonist composed of IL15 and an IL15Rα domain. This fusion protein was designed to bypass the need for endogenous IL15Rα to take advantage of IL15. It has been shown to activate proliferation and activity of NK. RLI-15 resulted in a potent effect in cell models. Recently the use of a CAR containing IL15\/IL15Rα and targeting CD19 in NK92 cells has also resulted in increased proliferation, cytokine secretion and cytotoxicity towards B-cell cancer cell lines. The inclusion of IL15\/IL15Rα fusion proteins to armor CARs represents a step forward in the fight against solid tumors.\u003c\/p\u003e\n\u003ch2\u003eProduct Description\u003c\/h2\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eHIV-based · VSV-G-pseudotyped · SIN=Yes\u003c\/span\u003e\u003cp\u003eIL15\/IL15Ra Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles ready to transduce nearly all types of mammalian cells, including primary and non-dividing cells. These particles result in expression of human IL15 (NM_000585.4) and IL15Rα (NM_002189.3) driven by an EF1a promoter, and a puromycin selection marker. IL15 and IL15Ra are fused via a glycine-serine linker.\u003c\/p\u003e\n\u003ch2\u003eTechnical Details\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eVector Type\u003c\/th\u003e\n\u003ctd\u003eHIV-based, VSV-G-pseudotyped lentiviral vector\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePayload \/ Construct\u003c\/th\u003e\n\u003ctd\u003eIL15\/IL15Ra fusion transgene\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget Antigen \/ Gene\u003c\/th\u003e\n\u003ctd\u003eIL-15 \/ IL-15Rα (IL15, IL15RA)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSignaling \/ Architecture\u003c\/th\u003e\n\u003ctd\u003eN\/A (transgene expression)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSelection Marker\u003c\/th\u003e\n\u003ctd\u003ePuromycin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReporter\u003c\/th\u003e\n\u003ctd\u003eNone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eBiosafety Level\u003c\/th\u003e\n\u003ctd\u003eBSL-2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSIN Vector\u003c\/th\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eThe lentivirus particles were produced in HEK293T cells in medium containing 90% DMEM + 10% FBS.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSupplied As\u003c\/th\u003e\n\u003ctd\u003eTwo vials (500 µl x 2) of lentivirus at a titer ≥10\u003csup\u003e7\u003c\/sup\u003e TU\/ml. The titer will vary with each lot; the exact value is provided with each shipment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e−80°C; avoid repeated freeze-thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eHazardous Shipping\u003c\/th\u003e\n\u003ctd\u003eUN3373\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eApplications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eExpression of human IL15\/IL15Ra in cells of interest.\u003c\/li\u003e\n\u003cli\u003eArming CAR-T and CAR-NK cells with IL15\/IL15Ra fusion protein.\u003c\/li\u003e\n\u003cli\u003eGenerate cell pools or stable cell lines expressing IL15\/IL15Ra following puromycin selection\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eBiosafety \u0026amp; Safety\u003c\/h2\u003e\n\u003cp\u003eTo generate an IL15\/IL15Ra expressing stable cell line, remove the growth medium 48 hours after transduction and replace it with fresh growth medium containing the appropriate amount of puromycin (as pre-determined from a killing curve, bpsbioscience.com\/cell-line-faq), for antibiotic selection of transduced cells, followed by clonal selection.  The lentiviruses are produced with a SIN (self-inactivation) lentivector which ensures self-inactivation of the lentiviral construct after transduction and after integration into the genomic DNA of the target cells. None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal and are not present in the lentivirus particle. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. BPS Bioscience recommends following all local federal, state, and institutional regulations and using all appropriate safety precautions. Troubleshooting Guide: Visit bpsbioscience.com\/lentivirus-faq for detailed troubleshooting instructions. For further questions, please email support@bpsbioscience.com.\u003c\/p\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\n\u003cstrong\u003e⚠ Safety Note:\u003c\/strong\u003e Avoid freeze\/thaw cycles.\u003c\/div\u003e\n\u003c\/div\u003e","brand":"BPS Bioscience","offers":[{"title":"500 uL x 2","offer_id":53322953130349,"sku":"78938","price":1315.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/78938-1.png?v=1778643137","url":"https:\/\/www.ebiohippo.com\/products\/il15-il15ra-lentivirus-bhv18200013","provider":"BioHippo","version":"1.0","type":"link"}